Latest Breaking News On - கேரி திஸ்ப்ரோவ் - Page 1 : comparemela.com
Biz Beat: Little Lamb Cafe to open, La Lupita open in Oxford
cecildaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cecildaily.com Daily Mail and Mail on Sunday newspapers.
U S to invest over 3 bln USD for COVID-19 antiviral medicines
longbeachstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from longbeachstar.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
DUBLIN, June 15, 2021 /PRNewswire/ Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft
® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns). Please see Important Safety Information for StrataGraft below.
Experience the interactive Multichannel News Release here:
This project was funded in part with $86 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), under contract HHSO100201500027 for Stratatech Corporation, a Mallinckrodt company, to develop StrataGraft.
BARDA venture capital program dedicates up to $500M for pandemic preparedness
Sponsored Content Provided By Pfizer
BARDA venture capital program dedicates up to $500M for pandemic preparedness
360Dx
Modern Healthcare Illustration / Getty Images
NEW YORK – The US Department of Health and Human Services Biomedical Advanced Research and Development Authority, or BARDA, has launched a new program to spur development of technologies to combat future pandemics and health emergencies.
For the initiative, the BARDA Division of Research, Innovation, and Ventures, or DRIVe, will support the BARDA Ventures program in a partnership with the nonprofit Global Health Investment Corporation.
According to a statement from HHS, BARDA Ventures will provide GHIC with a minimum of $50 million over five years, and the potential of up to $500 million over 10 years. In turn, GHIC will launch a global health security fund with matching capital from other investors.
vimarsana © 2020. All Rights Reserved.